Lead Product(s) : Camostatum
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)
Details : FOY-305 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 08, 2020
Lead Product(s) : Camostatum
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Camostatum
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male Subjects
Details : FOY-305 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 30, 2020
Lead Product(s) : Camostatum
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable